fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Psych Congress and NEI Congress 2024: Alkermes highlights key data on psychiatric treatments and narcolepsy research

Written by | 11 Nov 2024

Alkermes announced the presentation of research related to Lybalvi (olanzapine and samidorphan) and Aristada (aripiprazole lauroxil), the company’s commercial products in psychiatry, and ALKS 2680, an investigational medicine… read more.

FDA approves Lybalvi for schizophrenia and bipolar I disorder – Alkermes

Written by | 2 Jun 2021

Alkermes announced that the FDA has approved Lybalvi (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.